Protective effect of edaravone on cisplatin-induced injury in rat ovary


Kara O., KAYMAK E. , YAKAN B.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2022
  • Doi Number: 10.1007/s00404-022-06538-9
  • Title of Journal : ARCHIVES OF GYNECOLOGY AND OBSTETRICS
  • Keywords: Cisplatin, Edaravone, Apoptosis, Ovarium, Rat, OXIDATIVE STRESS, APOPTOSIS

Abstract

Purpose This study was aimed to evaluate the protective effect of edaravone on cisplatin-induced ovarian injury. Methods A total 40 female Wistar-Albino rats were utilized to form four groups: Group 1 (control group) (n = 10), no procedure was performed. Group 2 (cisplatin group) (n = 10), single-dose 7.5 mg/kg cisplatin was administered and no procedure was performed. Group 3 (edaravone group) (n = 10), single-dose 1 mg/kg edaravone was administered and no procedure was performed. Group 4 (cisplatin + edaravone group) (n = 10), single-dose 7.5 mg/kg cisplatin and 1 mg/kg edaravone were administered. Seventy-two hours later, ovaries were surgically extirpated in all groups. Malondialdehyde (MDA) levels and nitric oxide (NO) levels were studied in blood samples. In ovarian tissue samples, DNA damage and apoptosis were assessed using TUNEL method. Ovarian tissue damage was evaluated by immunohistochemical staining with caspase 3 and caspase 8. Results According to the findings obtained from the study, edaravone showed protective properties on ovarian damage due to cisplatin. MDA and NO levels were significantly higher in cisplatin group than other groups. Histopathological ovarian tissue damage in the cisplatin group was significantly higher than other groups. Similarly, DNA damage and apoptosis were higher in cisplatin group and this difference was found to be statistically significant. The immunohistochemical staining which was done using caspase 3 and caspase 8 was revealed that immunoreactive cells were statistically higher in cisplatin group than cisplatin + edaravone group. Conclusion Edaravone seems to be effective in prevention of ovarian damage and short-term treatment.